682 related articles for article (PubMed ID: 33792221)
21. Long-term outcomes following CAR T cell therapy: what we know so far.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
[TBL] [Abstract][Full Text] [Related]
22. [CAR-T therapy for multiple myeloma].
Ri M
Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
[TBL] [Abstract][Full Text] [Related]
23. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
25. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
26. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
27. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
28. BCMA CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract][Full Text] [Related]
29. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
30. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
[TBL] [Abstract][Full Text] [Related]
31. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
32. Update on the current and future use of CAR-T to treat multiple myeloma.
Gahvari Z; Brunner M; Schmidt T; Callander NS
Eur J Haematol; 2024 Apr; 112(4):493-503. PubMed ID: 38099401
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.
Wang B; Rajeeve S; Madduri D
Cancer J; 2021 May-Jun 01; 27(3):205-212. PubMed ID: 34549909
[TBL] [Abstract][Full Text] [Related]
34. Development of CAR-T cell therapies for multiple myeloma.
Gagelmann N; Riecken K; Wolschke C; Berger C; Ayuk FA; Fehse B; Kröger N
Leukemia; 2020 Sep; 34(9):2317-2332. PubMed ID: 32572190
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Dhakal B; Hari PN; Usmani SZ; Hamadani M
Bone Marrow Transplant; 2021 Jan; 56(1):9-19. PubMed ID: 32770147
[TBL] [Abstract][Full Text] [Related]
36. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
37. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
38. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
39. [Development of Novel Gene-Modified T-Cell Therapies(CAR-T, TCR-T)].
Kitano S
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1032-1037. PubMed ID: 38035829
[TBL] [Abstract][Full Text] [Related]
40. Cell-based immunotherapy approaches for multiple myeloma.
Kriegsmann K; Kriegsmann M; Cremer M; Schmitt M; Dreger P; Goldschmidt H; Müller-Tidow C; Hundemer M
Br J Cancer; 2019 Jan; 120(1):38-44. PubMed ID: 30518815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]